Related Experiment Videos
[Novelties and perspectives in asthma medicines]
1Laboratoire de Pharmacologie, Faculté de Médecine Paris Ouest.
Revue Des Maladies Respiratoires
|January 1, 1993
Summary
Researchers are exploring novel medications for improved efficacy and tolerability. Key areas include specific phosphodiesterase inhibitors, potassium channel openers, tachykinin antagonists, and anti-leukotrienes for respiratory conditions.
Area of Science:
- Pharmacology
- Respiratory Medicine
Context:
- Development of novel therapeutic agents for respiratory diseases is ongoing.
- Existing treatments have limitations in efficacy and side-effect profiles.
Purpose:
- To review emerging drug classes for respiratory conditions.
- To highlight potential therapeutic benefits and challenges of new drug candidates.
Summary:
- Specific phosphodiesterase inhibitors offer potential theophylline-like effects with fewer side effects.
- Potassium channel openers demonstrate potent bronchodilation but lack specificity and have side effects.
- Tachykinin antagonists present new avenues in respiratory physiopathology and treatment.
- Anti-leukotrienes provide anti-inflammatory benefits, potentially reducing steroid dependence.
Impact:
- Identifies promising drug classes for future respiratory therapies.
- Informs researchers about the potential and limitations of novel pharmacological approaches.